A Study on Technology Transfer and Access to Patented Biological Drugs with Special Reference to The Trips Agreement

Abstract

COVID-19 has rekindled the controversy of patents being an incentive or newlinedeterrent to access to medicine. It was realised that despite having proper medication, newlineand pharmaceuticals especially vaccines for the prevention and cure of an ailment newlinedisease, there was a vast disparity between the nations in access to those drugs, which newlineled to the recurrence of pandemics. However, the case is not limited to COVID-19 newlinealone, and many patented drugs, especially biological drugs, which play an essential newlinerole in curing diseases like cancer, arthritis, diabetes, HIV/ AIDS etc., are not newlineaffordable and accessible to the general public of third-world countries. Patent law newlineprovides a monopoly to the patent holder in terms of production and supply of the newlinedrugs. However, it also provides an inbuilt mechanism called technology transfer newlinewhich helps to maintain a balance between public interest in the form of health rights newlineand private rights of the patent holder i.e. patent rights. The TRIPS Agreement in its newlineobjectives and principles clearly mentions that the provisions of the Agreement can be newlineinterpreted by the member nations in accordance with their socio-economic structure, newlineand to disseminate technology transfer. During the DOHA Declaration on Public newlineHealth, the importance of technology and use of TRIPS Agreements flexibilities for newlineproviding access to pharmaceutical drugs was once again discussed. However, despite newlinethese flexibilities at the international framework, there is a lack of technology transfer newlinetaking place is reality. newlineThe research aims to analyse the extent of technology transfer for patented newlinebiological drugs in India. It also analyses how the TRIPS Agreement and domestic newlinepatent laws in countries like the United States, Brazil, South Africa and the European newlineUnion promote or hinder access to patented biological drugs. By examining the policy newlineframeworks, and the data available related to technology transfer in the WTO and by newlineexamining the extent of technology transfer of biological drugs in India, the study aims newlineto evaluate

Description

Keywords

Citation

item.page.endorsement

item.page.review

item.page.supplemented

item.page.referenced